Scutellarin inhibits cytochrome P450 isoenzyme 1A2 (CYP1A2) in rats.
Tun-Yu Jian, Jian-Chang He, Gong-Hao He, En-Fu Feng, Hong-Liang Li, Min Bai, Gui-Li Xu
Index: Phytother Res. 26(8) , 1226-30, (2012)
Full Text: HTML
Abstract
Scutellarin is the most important flavone glycoside in the herbal drug Erigeron breviscapus (Vant.) Hand.-Mazz. It is used frequently in the clinic to treat ischemic vascular diseases in China. However, the direct relationship between scutellarin and cytochrome P450 (CYP450) is unclear. The present study investigated the in vitro and in vivo effects of scutellarin on cytochrome P450 1A2 (CYP 1A2) metabolism. According to in vitro experiments, scutellarin (10-250 µM) decreased the formation of 4-acetamidophenol in a concentration-dependent manner, with an IC₅₀ value of 108.20 ± 0.657 µM. Furthermore, scutellarin exhibited a weak mixed-type inhibition against the activity of CYP1A2 in rat liver microsomes, with a K(i) value of 95.2 µM. Whereas in whole animal studies, scutellarin treatment for 7 days (at 5, 15, 30 mg/kg, i.p.) decreased the clearance (CL), and increased the T(1/2) (at 15, 30 mg/kg, i.p.), it did not affect the V(d) of phenacetin. Scutellarin treatment (at 5, 15, 30 mg/kg, i.p.) increased the AUC(0-∞) by 14.3%, 67.3% and 159.2%, respectively. Scutellarin at 30 mg/kg also weakly inhibited CYP1A2 activity, in accordance with our in vitro study. Thus, the results indicate that CYP1A2 is inhibited directly, but weakly, by scutellarin in vivo, and provide useful information on the safe and effective use of scutellarin in clinical practice.Copyright © 2012 John Wiley & Sons, Ltd.
Related Compounds
Related Articles:
2010-01-01
[Chem. Res. Toxicol. 23 , 171-83, (2010)]
2011-12-01
[J. Sci. Ind. Res. 65(10) , 808, (2006)]
The Japanese toxicogenomics project: application of toxicogenomics.
2010-02-01
[Mol. Nutr. Food. Res. 54 , 218-27, (2010)]
Developing structure-activity relationships for the prediction of hepatotoxicity.
2010-07-19
[Chem. Res. Toxicol. 23 , 1215-22, (2010)]
A predictive ligand-based Bayesian model for human drug-induced liver injury.
2010-12-01
[Drug Metab. Dispos. 38 , 2302-8, (2010)]